Virtual Reality Intervention to Improve Psychological Symptom Burden for Cancer Patients U
This clinical trial tests the safety, tolerability, and effectiveness of a virtual reality intervention to improve psychological symptom burden for cancer patients undergoing treatment. Virtual reality (VR) is a technology that allows users to experience and interact with three-dimensional, computer-generated environme
| Condition(s) | Adjustment Disorder, Anxiety Disorder, Depression, Hematopoietic and Lymphoid System Neoplasm, Malignant Solid Neoplasm, Cancer |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | This clinical trial tests the safety, tolerability, and effectiveness of a virtual reality intervention to improve psychological symptom burden for cancer patients undergoing treatment. Virtual reality (VR) is a technology that allows users to experience and interact with three-dimensional, computer-generated environments that simulate the real world or imagined settings. The VR intervention consists of a preloaded with immersive environments designed to engage the senses through simulated sights and sounds. This may include a walk through of a serene forest, exploring vibrant coral reefs, swimming with dolphins, or standing at the base of a majestic waterfall. These environments are created to provide a relaxing and engaging experience. Completing the VR intervention may be a safe and eff |
| Who can participate | Inclusion Criteria: * History of cancer * Age between 18 to 90 years * Undergoing in-patient chemotherapy, bone marrow transplant (BMT), chimeric antigen receptor (CAR)-t, \& out-patient chemotherapy Exclusion Criteria: * History of bipolar disorder, major depression, bipolar disorder, anxiety disorder, post traumatic stress disorder (PTSD), obsessive compulsive disorder (OCD), psychotic disorder, schizophrenia, personality disorder, substance use disorder other than caffeine or tobacco. History of suicidal ideation or attempt * History of treatment resistant depression, psychiatric hospitalization, syncope, transient ischemic attack (TIA), stroke, epilepsy, electroconvulsive therapy, benign positional vertigo, Meniere's disease |
| Ages | 18 Years to 90 Years |
| Sex | All |
| Lead sponsor | Mayo Clinic |
| Locations | Jacksonville, Florida, United States |
| Start date | 2025-10-08 |
| NCT ID | NCT07221409 |
| Official listing | https://clinicaltrials.gov/study/NCT07221409 |